# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Leonard Nimoy (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML017-SYN
- Date: 2026-03-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Carla Benedetti, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Four-week COPD review after starting tiotropium-olodaterol. **S**

## History of present illness

Mr. Nimoy returns four weeks after starting tiotropium-olodaterol two inhalations each morning. He feels a little less tight in the chest in the mornings and has cut his albuterol from once or twice a day to about four times a week. He still has to stop for breath after about 100 meters on level ground. The dose counter shows no missed doses. He has had no flare-up, increase in sputum, fever, or need for antibiotics or prednisone. He has no dry mouth, difficulty passing urine, palpitations, or tremor. He saw the pulmonologist this morning, and his 6-minute walk test was done in the pulmonary function laboratory. He starts pulmonary rehabilitation next week. **S**

| Element | Detail |
|---|---|
| Interval change | Mornings easier; still stops after about 100 meters |
| Reliever use | Albuterol about four times a week, down from once or twice a day |
| Adherence | No missed doses by dose counter |
| Exacerbations | None since intake, and none in the past 12 months |
| Medication tolerance | No dry mouth, urinary difficulty, palpitations, or tremor |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Breathless on walking about 100 meters or one flight of stairs; little cough; small amount of clear morning sputum |
| Cardiovascular | Negative | No chest pain, palpitations, orthopnea, or ankle swelling |
| Genitourinary | Negative | No hesitancy or retention |
| Psychiatric | Negative | Mood steady; no panic with breathlessness |

4 systems reviewed. **S**

## Current medications

- Albuterol 90 mcg/actuation inhaler, two inhalations as needed for breathlessness (prescribed by his previous clinician; used once or twice most days before intake) **S**
- Tiotropium-olodaterol 2.5/2.5 mcg soft mist inhaler, two inhalations once daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/76 mmHg; pulse 82 bpm; respirations 18/min; temperature 36.6 °C; oxygen saturation 93% on room air; weight 80.2 kg; BMI 23.4 kg/m². All vital signs are synthetic.

6-minute walk distance: 270 m (low). All results are synthetic.

## Physical examination

| System | Finding |
|---|---|
| General | Speaks in full sentences; no use of accessory muscles at rest |
| Lungs | Reduced breath sounds throughout with prolonged expiration; no wheeze or crackles |
| Cardiovascular | Regular rhythm at 82 per minute; no edema |
| Inhaler technique | Correct with his soft mist inhaler: slow, deep breath with the dose and a ten-second breath hold |

All examination findings are synthetic. **S**

## Assessment and plan

1. **COPD, GOLD 3, group B** (J44.9). Slightly better on dual bronchodilator therapy: CAT 19, down from 22, with less reliever use, but still mMRC grade 3. 6-minute walk 270 m with a lowest saturation of 89 percent, and resting saturation 93 percent, so he meets no criterion for long-term or exertional oxygen. Blood eosinophils 0.18 x10³/µL and no exacerbations, so an inhaled corticosteroid would add risk without benefit. The pulmonologist agrees with the GOLD grade and group and with the current inhaler. **S**
   - Continue tiotropium-olodaterol two inhalations each morning and albuterol as needed.
   - Pulmonary rehabilitation starts next week: 24 sessions over eight weeks, with a repeat 6-minute walk at the end.
   - Written COPD action plan reviewed.
   - PCV20 was planned today but was out of stock; give at the next visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | COPD Assessment Test (CAT) | Every visit | Completed today | 19, down from 22 at intake; a change of 2 or more is meaningful |
| Survey | mMRC dyspnea grade | Every visit | Completed today | Grade 3, unchanged |
| Survey | Exacerbation history and GOLD group | Every visit | Completed today | No moderate or severe exacerbation in the past 12 months; group B |
| Examination | Pulse oximetry | Every visit | Completed today | 93 percent at rest on room air |
| Self-management | Smoking status and cessation support | Every visit | Completed today | Former smoker; no tobacco for about 30 years |
| Examination | BMI and nutritional status | Every visit | Completed today | BMI 23.4; weight stable |
| Examination | Inhaler technique and adherence | Every visit | Completed today | Correct technique; no missed doses |
| Examination | 6-minute walk test | At pulmonary rehabilitation entry and exit, and for oxygen assessment | Completed today | 270 m at rehabilitation entry; lowest saturation 89 percent |
| Examination | Long-term oxygen assessment | As indicated: resting saturation 88 percent or less, confirmed twice at least three weeks apart | Completed today | Not met: 93 percent at rest and 89 percent at the lowest on exertion; no oxygen prescribed |
| Laboratory | Arterial blood gas | As indicated: resting saturation 92 percent or less, oxygen qualification, or suspected hypercapnia | Not indicated | Resting saturation 93 percent; no sign of hypercapnia |
| Examination | Spirometry | At diagnosis, then at least yearly and with significant clinical change | Up to date | Diagnostic spirometry at intake: post-bronchodilator FEV1/FVC 0.43, FEV1 46 percent predicted; next in one year |
| Laboratory | Alpha-1 antitrypsin | Once, at diagnosis | Up to date | 138 mg/dL at intake, normal; not repeated |
| Laboratory | Blood eosinophil count | At baseline and when an inhaled corticosteroid is considered | Up to date | 0.18 x10³/µL at intake; no inhaled corticosteroid while there are no exacerbations |
| Examination | ECG and cardiovascular risk assessment | At baseline and after exacerbations | Up to date | Intake ECG in sinus rhythm with no abnormality; blood pressure normal |
| Survey | Mood and comorbidity screening | At diagnosis and yearly | Up to date | PHQ-9 3 and GAD-2 1 at intake; no reflux, sleep, or nutrition concern |
| Referral | Pulmonology consultation | When the diagnosis, severity, or treatment needs specialist review | Completed today | Seen today; GOLD 3, group B confirmed; current inhaler continued |
| Referral | Pulmonary rehabilitation | Stable mMRC 2 or more or CAT 10 or more; within three weeks of any hospital stay for an exacerbation | Referred | Program begins next week |
| Medication safety | Vaccination status | Reviewed yearly | Deferred | High-dose influenza vaccine this past autumn, zoster series complete, Tdap within ten years. PCV20 was planned today but the clinic was out of stock, so it was not given; to be given at the next visit |
| Imaging | Low-dose chest CT | As indicated, or yearly lung cancer screening if eligible | Not indicated | No suspected complication; not eligible for screening, because he quit more than 15 years ago |

## Goal progress

- CAT score at least 2 points lower by the three-month review. In progress; target 2026-05-12. **S**
- 6-minute walk distance at least 30 meters farther after pulmonary rehabilitation. In progress; target 2026-05-12. **S**
- No moderate or severe exacerbation over the six months after starting maintenance therapy. In progress; target 2026-08-11. **S**
- Correct soft mist inhaler technique and a daily maintenance dose. Outcome by 2026-03-10: Correct technique on demonstration and no missed doses by dose counter at four weeks. **S**

## Guideline basis

- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2025 report (2025), Global Initiative for Chronic Obstructive Lung Disease
- CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026), Aether Forge
- Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline (2023), American Thoracic Society (Am J Respir Crit Care Med 2023;208(4):e7-e26)
- Home Oxygen Therapy for Adults with Chronic Lung Disease: An Official American Thoracic Society Clinical Practice Guideline (2020), American Thoracic Society (Am J Respir Crit Care Med 2020;202(10):e121-e141)

## Follow-up

- Pulmonary rehabilitation from next week. COPD review in two months, after rehabilitation. **S**
- Next scheduled visit 2026-05-12: three-month COPD review after pulmonary rehabilitation. **S**
